INVO Fertility (IVF) investor relations material

Mission and strategy

• Focused on making advanced fertility care effective, accessible, and empowering through innovation and a patient-centered approach.

• Expanding from a device heritage to a comprehensive fertility healthcare provider, leveraging proprietary technology and clinic operations.

• Growth strategy centers on acquiring profitable U.S. fertility clinics and related businesses, with a robust acquisition pipeline.

• Emphasizes building new clinics in secondary U.S. markets and acquiring ancillary fertility technologies and services.

• Offers a public company platform as an alternative to private equity for clinic owners.

Financial performance and growth

• Clinic revenue grew from $1.7M in 2022 to $7.7M in 2024, with $6.1M in the first nine months of 2025.

• Adjusted EBITDA loss reduced from -$8.4M in 2022 to -$2.2M in 2024, showing momentum toward breakeven.

• Acquisition of Wisconsin Fertility Institute was a key driver for revenue and EBITDA improvement.

• Cash and cash equivalents stood at $355,891 as of September 2025, with total assets of $18.8M.

• Market capitalization was $6.9M with a stock price of $0.86 as of March 2026.

Operations and clinic network

• Operates four fertility clinics in Wisconsin, Indiana, Georgia, and Alabama, performing over 1,000 cycles in 2025.

• Wisconsin Fertility Institute is the largest contributor to positive cash flow and uses telehealth to expand reach.

• Bloom Fertility Center has achieved self-sustainability and plans to expand services and technology.

• Recent acquisition of Family Beginnings in Indianapolis, IN, in February 2026.

• Clinics leverage novel technologies to increase capacity and efficiency.